A Phase I/II, Single Center, Partially Observer-Blind, Controlled, Randomized Study to Explore Safety and Immunogenicity in Healthy Adult Subjects who Receive Either One Dose of Chiron Combined MenC-Hib Conjugate Vaccine, OR Separate Administration of Chiron Hib Conjugate Vaccine (VaxemHib) and Chiron MenC Conjugate Vaccine (Menjugate), OR One Dose of Menjugate, OR One Dose of VaxemHib
- Conditions
- Active immnunisation for the prevention of invasive disease caused by N. Meningitidis serogroup C and H. influenzae type bMedDRA version: 6.1Level: PTClassification code 10027249
- Registration Number
- EUCTR2004-000767-10-IT
- Lead Sponsor
- CHIRO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method